Trial reportInternational journal of general medicine2025
Comparative Evaluation of Remimazolam Besylate versus Propofol for Pediatric MRI Sedation: Safety, Recovery, and Adverse Event Profiles.
Trial report in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- EDFrontiers in medicine · 2026Trial
- Local Urticarial Reaction Above the Site of an Intravenous Cannula: Possible Allergy to Remimazolam in a Fourteen-Year-Old Adolescent.Journal of medical cases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the safety and efficacy of remimazolam besylate compared with propofol for pediatric MRI sedation. Methods: Seventy-nine children undergoing MRI were randomly assigned to the remimazolam (R, n=39) or propofol (P, n=40) group. The primary observation indicator was the sedation success rate. Secondary indicators included the frequency of supplemental dosing, induction time, recovery time, and the incidence of adverse events (hypoxia, severe hypoxia, injection pain, hypotension, and bradycardia). Logistic regression and Spearman correlation were used to identify risk factors for adverse events. Results: Sedation success rates were similar between groups (R: 92.3%, P: 95.0%; Conclusion: Remimazolam besylate and propofol are both safe and effective for pediatric MRI sedation, but remimazolam besylate is superior due to faster recovery and fewer adverse events. Clinical Trial Number: This study was prospectively registered with the Chinese Clinical Trial Registry (ChiCTR), registration number: ChiCTR2500097093.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.